SEARCH

SEARCH BY CITATION

References

  • 1
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:12451255.
  • 2
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:6267.
  • 3
    Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:12741283.
  • 4
    Forner A, Reig ME, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:6174.
  • 5
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329338.
  • 6
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:19071917.
  • 7
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:10201022.
  • 8
    European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908943.
  • 9
    Beaugrand M, Sala M, Degos F, Sherman M, Bolondi L, Evans T, et al. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an international randomized double-blind placebo-controlled study in 747 patients. J Hepatol 2003;42:17A.
  • 10
    Burrel M, Reig M, Forner A, Barrufet M, Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using DC Beads. Implications for clinical practice and trial design. J Hepatol 2012;56:13301335.
  • 11
    Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012;35:11191128.
  • 12
    Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378390.
  • 13
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:2534.